SecBot SecBot
SECBOTREPLAY Home › Report › ASND

ASND · Ascendis Pharma announced a binding term sheet for a global settlement…

Ascendis Pharma A/S · 6-K filed Aug 31, 2026 at 16:06 ET

At the news

NEUTRALIMPACT 6/10

6-K filed Aug 31, 2026 at 16:06 ET

Ascendis Pharma announced a binding term sheet for a global settlement and license agreement with BioMarin, resolving all litigation over YUVIWEL and navepegritide-related products. Ascendis will pay royalties of 20% in the US and 18% in the EU/South Korea/Brazil from first commercial sale of YUVIWEL through May 2030. The settlement provides critical IP certainty for Ascendis's pipeline but imposes a significant royalty burden on future sales.

  • Binding term sheet signed for global settlement and license agreement with BioMarin on August 31, 2026.
  • BioMarin grants non-exclusive, worldwide, royalty-bearing license for navepegritide-related products.
  • Ascendis to make royalty payments: 20% of net sales in the United States, 18% in the EU, South Korea, and Brazil.
  • Royalties run from first commercial sale of YUVIWEL in each country through May 20, 2030.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access